Superiority of escitalopram to paroxetine in the treatment of depression

European Neuropsychopharmacology

Volumn 19, Issue 4, 2009, Pages 229-237

  Kasper, Siegfried ^a   Baldwin, David S ^b   Larsson Lönn, Sara ^c   Boulenger, Jean Philippe ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Escitalopram; ; Major depressive disorder (MDD); ; Paroxetine; Selective serotonin reuptake inhibitors (SSRIs); ; Severe depression;

Indexed keywords

ESCITALOPRAM; PAROXETINE;

BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LONG TERM CARE; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PAROXETINE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 60749112308     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.12.003     Document Type: Review

References (27)

1. Baldwin D.S., Cooper J.A., Huusom A.K., and Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int. Clin. Psychopharmacol. 21 (2006) 159-169
2. Boulenger J.P. Residual symptoms of depression: clinical and theoretical implications. Eur. Psychiatr. 19 (2004) 209-213
3. Boulenger J.P., Huusom A.K., Florea I., Baekdal T., and Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr. Med. Res. Opin. 22 (2006) 1331-1341
4. Burke W.J. Escitalopram. Expert Opin. Investig. Drugs 11 (2002) 1477-1486
5. Colonna L., Andersen H.F., and Reines E.H. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr. Med. Res. Opin. 21 (2005) 1659-1668
6. Egger M., and Smith G.D. Meta-analysis. Potentials and promise. Br. Med. J. 315 (1997) 1371-1374
7. Egger M., Smith G.D., and Phillips A.N. Meta-analysis: principles and procedures. Br. Med. J. 315 (1997) 1533-1537
8. El Mansari M.E., Wiborg O., Mnie-Filali O., Benturquia N., Sanchez C., and Haddjeri N. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int. J. Neuropsychopharmacol. 10 (2007) 31-40
9. Golden R.N., Nemeroff C.B., Mcsorley P., Pitts C.D., and Dube E.M. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry 63 (2002) 577-584
10. Kasper S. Unique mechanism of action for escitalopram: does it hold the promise?. Int. J. Psychiatry Clin. Pract. 8 Suppl.1 (2004) 15-18
11. Kasper S., Lemming O.M., and De Swart H. Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology 54 (2007) 152-159
12. Khan A., Bose A., Alexopoulos G.S., Gommoll C., Li D., and Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Investig. 27 (2007) 481-492
13. Kirsch I., Moore T.J., Scoboria A., and Nicholls S.S. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev. Treat. 5 (2002) 23
14. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., and Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5 (2008) e45
15. 123I] ADAM SPECT study. Psychopharmacology (Berl) 191 (2007) 333-339
16. Leiberman J.A., Greenhouse J., Hamer R.M., Krishnan H.R., Nemeroff C.B., Sheehan D.V., Thase M.E., and Keller M.B. Neuropsychopharmacology 30 (2005) 455-460
17. Lepola U.M., Loft H., and Reines E.H. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. 18 (2003) 211-217
18. Lepola U., Wade A., and Andersen H.F. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int. Clin. Psychopharmacol. 19 (2004) 149-155
19. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., Lam R.W., Lepine J.P., Moller H.J., Nutt D.J., Rouillon F., Schatzberg A.F., and Thase M.E. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int. Clin. Psychopharmacol. 22 (2007) 323-329
20. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 20 (2005) 131-137
21. Oswald P., Souery D., and Kasper S. Predictive factors of resistance to antidepressant treatments: results from a European multicentre study. Eur. Neuropsychopharmacol. 15 (2005) S326-S327
22. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin. Pharmacol. Toxicol. 99 (2006) 91-95
23. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174 (2004) 163-176
24. Szadoczky E., Rozsa S., Zambori J., and Furedi J. Predictors for 2-year outcome of major depressive episode. J. Affect. Disord. 83 (2004) 49-57
25. Thase M.E. Comparing the methods used to compare antidepressants. Psychopharmacol. Bull. 36 (2002) 4-17
26. Trivedi M.H., Pigotti T.A., Perera P., Dillingham K.E., Carfagno M.L., and Pitts C.D. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J. Clin. Psychiatry 65 (2004) 1356-1364
27. Wade A., Michael Lemming O., and Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. 17 (2002) 95-102